IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

IAVARONE, MASSIMO ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.755
NA - Nord America 3.499
AS - Asia 2.220
SA - Sud America 187
AF - Africa 41
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 6
Totale 12.728
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.373
GB - Regno Unito 3.026
CN - Cina 959
DE - Germania 940
IT - Italia 661
SE - Svezia 605
SG - Singapore 468
RU - Federazione Russa 331
UA - Ucraina 278
FR - Francia 210
IE - Irlanda 209
IN - India 201
TR - Turchia 164
KR - Corea 153
FI - Finlandia 122
BR - Brasile 107
EU - Europa 105
CA - Canada 102
HK - Hong Kong 92
NL - Olanda 92
PL - Polonia 91
CO - Colombia 57
DK - Danimarca 52
GR - Grecia 46
ID - Indonesia 37
JP - Giappone 36
TW - Taiwan 35
BE - Belgio 21
MX - Messico 20
AU - Australia 14
ES - Italia 14
UZ - Uzbekistan 14
EG - Egitto 13
CH - Svizzera 11
SL - Sierra Leone 10
TH - Thailandia 9
RO - Romania 8
AT - Austria 7
CL - Cile 6
EC - Ecuador 6
NZ - Nuova Zelanda 6
PK - Pakistan 6
PT - Portogallo 6
AR - Argentina 5
CZ - Repubblica Ceca 5
EE - Estonia 5
MA - Marocco 5
MM - Myanmar 5
MY - Malesia 5
SA - Arabia Saudita 5
SC - Seychelles 5
VN - Vietnam 5
IL - Israele 4
PH - Filippine 4
BG - Bulgaria 3
GH - Ghana 3
HU - Ungheria 3
IR - Iran 3
PA - Panama 3
PE - Perù 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
IQ - Iraq 2
LT - Lituania 2
LU - Lussemburgo 2
ZA - Sudafrica 2
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
NG - Nigeria 1
PS - Palestinian Territory 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
UY - Uruguay 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.828
Salva come PNG Salva come JPEG
Città #
Southend 2.901
Chandler 437
Frankfurt am Main 336
Singapore 326
Seattle 263
Jacksonville 237
Beijing 219
Milan 208
Dublin 195
Princeton 190
Wilmington 159
Ashburn 142
Nanjing 129
Ann Arbor 126
Council Bluffs 114
Mountain View 100
Redmond 95
Houston 92
Santa Clara 90
Warsaw 86
Serra 80
Hong Kong 75
Dearborn 74
Toronto 71
Andover 67
Boardman 67
Bengaluru 66
Sakarya 64
Des Moines 62
Shanghai 62
Woodbridge 61
Bogotá 57
Fairfield 55
Somerville 44
Jinan 42
Grafing 41
Helsinki 39
New York 39
Guangzhou 37
Redwood City 35
Shenyang 35
Athens 31
Turin 31
Berlin 28
Saint Petersburg 28
Phoenix 27
Changsha 26
Hanover 26
Nanchang 23
Tianjin 22
Bitonto 20
Brussels 20
Mumbai 20
Hangzhou 19
Jakarta 19
Los Angeles 19
Zhengzhou 18
Fuzhou 17
Rome 17
Cambridge 16
Hefei 16
Kunming 16
Hebei 14
Menlo Park 14
Munich 14
San Diego 13
Auburn Hills 12
Eitensheim 12
Sunnyvale 12
São Paulo 12
Taipei 12
Roxbury 11
Taichung 11
Columbus 10
Nuremberg 10
London 9
Montreal 9
Palaiseau 9
Piscataway 9
Shenzhen 9
Fremont 8
Jiaxing 8
Ottawa 8
Taiyuan 8
Verona 8
Bologna 7
Falls Church 7
Kiez 7
Medford 7
Ningbo 7
Padova 7
Pune 7
Quanzhou 7
Taizhou 7
Wuhan 7
Bergamo 6
Cairo 6
Chengdu 6
Chicago 6
Costa Mesa 6
Totale 8.419
Salva come PNG Salva come JPEG
Nome #
Multimodality treatment of hepatocellular carcinoma : How field practice complies with international recommendations 381
Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs 342
PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma 336
Experience Wwith Early Sorafenib Treatment with Mtor Inhibitors in Hepatocellular Carcinoma Recurring after Liver Transplantation 248
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years 243
Excellent 5-year overall survival in patients with HBV-related cirrhosis undergoing liver transplantation for hepatocellular carcinoma 215
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 214
3 years of Adefovir and Lamivudine combination therapy minimized the risk of genotypic resistance to ADV in Lam resistant patients 212
Serum expression of lectin reactive alphafetoprotein, des-gamma-carboxy prothrombin, Golgi protein-73 antigen and antibody, for the diagnosis of hepatocellular carcinoma 208
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistant patients with HBeAg-negative chronic hepatitis B 197
Assessing tumor angiogenesis : Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells 194
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B 184
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 184
Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma 182
Versant 3.0 and Cobas Taqman for monitoring serum HBV-DNA in HBeAg-negative patients under lamivudine-adefovir combinant therapy 178
High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 178
A prospective study of peripheral blood alpha-fetoprotein messenger RNA in cirrhotic patients at risk of hepatocellular carcinoma 175
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine 173
Natural history of HCC developing in HBV-related cirrhotic patients undergoing antiviral treatment with nucleos(t)ide analogues 171
Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B 169
Very early add-on adefovir therapy in patients with sub-optimal virological response to lamivudine 164
Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy 163
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation 163
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma 161
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 158
Recist versus easl criteria for the evaluation of HCC response to sorafenib 157
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices : a 12-year prospective cohort study 156
Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL) : a randomised, controlled, phase 2b/3 trial 156
Local circulation of VEGF is involved in collateral vessels development in cirrhotic patients with portal hypertension 155
Six years of “on demand” LAM ± ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 155
Add on Adefovir prevents the emergence of ADV resistance in Lamivudine-resistant patients : a 4-year study 155
Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma 155
Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis 155
Prevalence and natural history of portal vein thrombosis, evaluated by contrast enhanced ultrasonography (CEUS), in patients with hepatocellular carcinoma 154
Transient elastography (TE) accurately predicts liver fibrosis stage in patients with chronic hepatitis B 154
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudineresistant chronic hepatitis B 152
Entecavir is an effective treatment for NUC-naive chronic hepatitis B patients in clinical practice : 48-week data from a large multicenter cohort study 148
The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma 147
Four years of Adefovir add-on in 145 lamivudine resistant patients with chronic hepatitis B : low risk of genotypic resistance to ADV and prevention of virologic breakthrough 146
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 146
Effectiveness of entecavir for the treatment of nuc-naïve chronic hepatitis B patients : a large multicenter cohort study in clinical practice 145
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 144
Effectiveness of entecavir for the treatment of NUC-naïve chronic hepatitis B patients : A large multicenter cohort study in clinical practice 142
Field practice with sorafenib in advanced HCC : effectiveness confirmed, reduced tolerability compared to registration trials 141
Low risk of hepatitis B reactivatioin in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 141
Six years of on demand LAM +/- ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with hbeag-negative cirrhosis 139
Chemoembolization with epirubicin drug eluting beads to treat early and intermediate hepatocellular carcinoma 139
Global Antiviral Journal “Bridging the Sciencies, HIV, HBV, HCV and Emerging Viruses” 136
Prospective validation of immunohistological stain for glypican-3 (GPC-3) in the early diagnosis of hepatocellular carcinoma 135
The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound (US) 134
Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients 134
Prospective study of dysplastic nodules in cirrhosis : correlation with CT vascular pattern, histology and development of hepatocellular carcinoma 131
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 131
The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma 131
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 130
High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B 129
The natural history of macroregenerative nodules prospectively detected in cirrhotic patients under surveillance 129
Prospective study of dysplastic nodes in cirrhotic patients : correlation with CT vascular pattern 129
Congenital Hepatic Fibrosis as a Cause of Recurrent Cholangitis: A Case Report and Review of the Literature 128
Low resistance to adefovir combined with lamivudine : a 3-year study of 145 lamivudine-resistant hepatitis B patients 127
Prospective validation of immunohistological stain for glypican-3 (GPC-3) in the early diagnosis of hepatocellular carcinoma 126
Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib 125
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin 124
Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients 123
A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene 122
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib 120
Prospective validation of AASLD guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients 116
Prospective study of dysplastic nodules in cirrhosis : correlation with CT vascular pattern, histology and development of hepatocellular carcinoma 114
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics 114
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B 113
Hepatocellular carcinoma in patients with compensated HCV-related cirrhosis responding to interferon : A 5-year follow-up study 111
Progressive decline of HBsAg titers in longterm virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 111
Low risk of hepatocellular carcinoma recurrence after liver transplantation : a 3-year follow-up study in 78 patients with chronic hepatitis B 107
Maintained HBV suppression in lamivudine-resistant patients treated with adefovir and lamivudine combination : A 4- year cohort study in 63 patients 105
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis 104
High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis 104
Six years of "on demand" LAM plus ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis 103
Interventional radiology image-guided locoregional therapies (Lrts) and immunotherapy for the treatment of hcc 103
Cholangiocarcinoma in Cirrhosis : Value of Hepatocyte Specific Magnetic Resonance Imaging 101
Progressive decline of HBsAg titers in long-term virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B 98
Sorafenib treatment of advanced hepatocellular carcinoma : a post-marketing study 96
Role of antiviral treatment for HCC prevention 87
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma 83
Hepatitis B-related hepatocellular carcinoma 81
Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19 80
Sorafenib in Clinical Practice: Evidence-Based Use or Abuse? Reply 78
Field-practice study of sorafenib therapy for hepatocellular carcinoma : a prospective multicenter study in Italy 74
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound 70
HBV-related HCC, clinical issues and therapy 69
Clinical Impact of a Protocol Involving Cone-Beam CT (CBCT), Fusion Imaging and Ablation Volume Prediction in Percutaneous Image-Guided Microwave Ablation in Patients with Hepatocellular Carcinoma Unsuitable for Standard Ultrasound (US) Guidance 64
An unprecedented challenge: The north italian gastroenterologist response to COVID-19 60
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration 54
HBV infection and hepatocellular carcinoma 53
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis 47
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 42
null 3
Totale 13.464
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.347
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.347
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020242 0 0 0 0 0 0 0 0 0 127 80 35
2020/20211.556 76 109 134 20 123 97 91 108 182 89 379 148
2021/20221.328 103 78 47 96 78 69 110 127 144 197 56 223
2022/20231.539 177 157 119 177 183 292 33 99 177 24 78 23
2023/20241.167 39 71 52 64 306 78 81 76 65 75 119 141
2024/20251.418 106 298 62 234 185 65 68 251 146 3 0 0
Totale 13.464